CATALYSIS Advises Microdialysis Pioneer CMA Microdialysis AB on the Sale of its Preclinical Microdialysis Assets to Harvard Bioscience, Inc.

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive strategic advisor to CMA Microdialysis AB on the sale of its preclinical microdialysis assets and related intellectual property to Harvard Bioscience, Inc. Financial terms were not disclosed.

CMA Microdialysis AB (Solna, Sweden) is a privately held manufacturer of microdialysis products. Founded in 1984, the company pioneered the microdialysis technique for in vivo sampling and monitoring of organs and tissues. As part of the transaction, Harvard Bioscience, Inc. will acquire the rights to the name CMA Microdialysis. CMA Microdialysis will be renamed to Dipylon Medical AB and will continue to focus on the development and marketing of clinical microdialysis solutions for human use. In addition, the leading Eirus system for continuous glucose monitoring for intensive care will be developed within the new Eirus Medical business unit. For further information, visit or

Harvard Bioscience, Inc. (Holliston, MA, United States) (NASDAQ: HBIO) is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. Harvard Bioscience sells its products to thousands of researchers in over 100 countries primarily through its 850 page catalogue (and various other specialty catalogues), its website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via a field sales organization. Harvard Bioscience has sales and manufacturing operations in the United States, the United Kingdom, Germany and Spain with additional facilities in France and Canada. For further information, visit

CATALYSIS Advises Life Science Innovators.  Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK.